Cambridge Healthtech Institute's Fourth Annual

Engineering Next-Generation Cancer Immunotherapies

( 次世代癌症免疫疗法的开发 )

New Protein Engineering Science and Technology to Support the Development of Novel Immunotherapeutics and Treatment Combinations

2018年1月8日 - 9日

 

A succession of strong clinical successes with antibodies against checkpoint targets has spawned a surge of interest from across the industry in the development of antibody immunotherapeutics and treatment combinations. The major challenges facing those now entering the field include establishing clinical proof of concept, product and target differentiation, selection of patient responders and the rational design of effective immunotherapy combinations. Cambridge Healthtech Institute's Fourth Annual Engineering Next-Generation Cancer Immunotherapies offers presentations of protein engineering strategies to improve the efficacy of immunotherapeutics and drive the progress of more personalized treatments in this space.

Preliminary Agenda


KEYNOTE PRESENTATION:
Antibody Product Trends in Immuno-Oncology

Partha Chowdhury, Ph.D., Senior Director and Head, Antibody Discovery, Sanofi Genzyme


ANTIBODY ENGINEERING CHALLENGES FOR IMMUNOTHERAPEUTICS

Optimization of Immune Regulatory Antibodies for Depletion of Regulatory T Cells

Frederick Arce-Vargas, M.D., Ph.D., Research Associate, Cancer Institute, University College London, United Kingdom

The Impact of mAb Format in Targeting the Tumor Microenvironment

Stephen Beers, Ph.D., Associate Professor, Cancer Immunology and Immunotherapy, University of Southampton, United Kingdom

Novel Therapeutic Antibodies for Cancer Isolated from Single Human B-Cells

Edward F. Patz, Jr., M.D., Professor, Radiology, Pharmacology and Cancer Biology Duke University Medical Center

Manipulation of B Cell Subsets to Generate High Affinity Antibodies

Ali Zarrin, Ph.D., Scientist, Immunology, Genentech


IMMUNOTHERAPY COMBINATIONS

Update on Clinical Progress of Immunotherapy Combinations

Gregory Daniels, M.D., Ph.D., Assistant Clinical Professor, Medicine, Moores Cancer Center, University of California, San Diego

Innovative Clinical Trial Designs and Biomarker Studies to Support the Development of Immunotherapy Combinations

Vamsidhar Velcheti, M.D., Professor, Medicine, Cleveland Clinic Lerner College of Medicine


EMERGING PATHWAYS AND TARGETS FOR CANCER IMMUNOTHERAPY

Epigenomic Mapping to Discover Novel Immunotherapy Targets

Pandurangan Vijayanand, M.D., Ph.D., Associate Professor, Vaccine Discovery, La Jolla Institute for Allergy and Immunology

Engineering to Enhance or Control Immunostimulatory Agonistic Antibodies

Andrew Weinberg, Ph.D., CSO, President, AgonOx

Targeted Mass Spectrometry for Cancer Epitope Discovery

Paul Armistead, M.D., Ph.D., Associate Professor, Medicine, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill


NOVEL IMMUNOTHERAPIES

Efficacy of CAR-T Cells and Other Immunotherapies

Dimiter S. Dimitrov, Ph.D., Senior Investigator, Protein Interactions Section, Cancer and Inflammation Program, National Cancer Institute, NIH

Development of Neoantigen-Based Cancer Vaccines

Laszlo Radvanyi, Ph.D., Senior Vice President, Immuno-Oncology Translational Innovation Platform, EMD Serono Research and Development Institute

New Immunomodulatory Target to Release Immunosuppression in the Tumor Microenvironment

Li Peng, Ph.D., Vice President, Antibody Engineering and Protein Sciences, Palleon Pharmaceuticals

Achieving Broad Tumor Coverage by Targeting Cancer Carbohydrate Antigens

G. Jonah Rainey, Ph.D., Executive Director, Research, MabVax Therapeutics Holdings, Inc.


* 活动内容有可能不事先告知作更动及调整。